Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Mar;79(9-10):1462–1467. doi: 10.1038/sj.bjc.6690233

Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer

K Takeda 1, S Negoro 1, S Kudoh 3, K Okishio 3, N Masuda 5, M Takada 5, M Tanaka 2, T Nakajima 4, T Tada 6, M Fukuoka 7
PMCID: PMC2362741  PMID: 10188891

Abstract

A study was undertaken to determine the maximum tolerated dose, the dose-limiting toxicities, and the response rate of irinotecan administered weekly with concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung cancer. In a phase I/II clinical trial, patients with histologically documented, surgically unresectable stage IIIA or IIIB non-small cell lung cancer (NSCLC) were enrolled. Irinotecan was administered as a 90 min intravenous infusion once weekly for 6 weeks. The starting dose was 30 mg m−2 and dose escalation was done in 15 mg m−2 increments. Dose-limiting toxicity was defined as grade 3 nonhaematologic toxicity (excluding nausea, vomiting and alopecia) or grade 4 haematologic toxicity according to the WHO criteria. Radiation was delivered to the primary tumour and regional lymph nodes (40 Gy), followed by a boost to the primary tumour (20 Gy). Twenty-seven patients were entered into this study at three irinotecan dose levels (30, 45 and 60 mg m−2). Twenty-six eligible patients were evaluated for toxic effects and clinical outcome. Severe oesophagitis, pneumonitis, and diarrhoea occurred at 45 and 60 mg m−2. Three of the five patients given 60 mg m−2 developed grade 3 or 4 oesophagitis and pneumonitis. In addition, one patient died of pneumonitis after completing therapy at 45 mg m−2 in the phase II study. The objective response rate was 76.9% (95% CI, 53.0–88.9%). Oesophagitis, pneumonitis, and diarrhoea are the dose-limiting toxicities of weekly irinotecan combined with thoracic irradiation. The maximum tolerated dose and the dose for the phase II study were 60 and 45 mg m−2 wk−1, respectively. This combined therapy for locally advanced non-small cell lung cancer is promising and shows acceptable toxicity. © 1999 Cancer Research Campaign

Keywords: irinotecan, chemoradiotherapy, clinical trial, radiosensitization

Full Text

The Full Text of this article is available as a PDF (95.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andoh T., Ishii K., Suzuki Y., Ikegami Y., Kusunoki Y., Takemoto Y., Okada K. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci U S A. 1987 Aug;84(16):5565–5569. doi: 10.1073/pnas.84.16.5565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Dillman R. O., Seagren S. L., Propert K. J., Guerra J., Eaton W. L., Perry M. C., Carey R. W., Frei E. F., 3rd, Green M. R. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990 Oct 4;323(14):940–945. doi: 10.1056/NEJM199010043231403. [DOI] [PubMed] [Google Scholar]
  3. Douple E. B. Platinum-radiation interactions. NCI Monogr. 1988;(6):315–319. [PubMed] [Google Scholar]
  4. Friess G. G., Baikadi M., Harvey W. H. Concurrent cisplatin and etoposide with radiotherapy in locally advanced non-small cell lung cancer. Cancer Treat Rep. 1987 Jul-Aug;71(7-8):681–684. [PubMed] [Google Scholar]
  5. Fukuoka M., Niitani H., Suzuki A., Motomiya M., Hasegawa K., Nishiwaki Y., Kuriyama T., Ariyoshi Y., Negoro S., Masuda N. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol. 1992 Jan;10(1):16–20. doi: 10.1200/JCO.1992.10.1.16. [DOI] [PubMed] [Google Scholar]
  6. Holsti L. R., Mattson K. A randomized study of split-course radiotheray of lung cancer: long term results. Int J Radiat Oncol Biol Phys. 1980 Aug;6(8):977–981. doi: 10.1016/0360-3016(80)90104-2. [DOI] [PubMed] [Google Scholar]
  7. Ihde D. C., Minna J. D. Non-small cell lung cancer. Part II: Treatment. Curr Probl Cancer. 1991 May-Jun;15(3):105–154. doi: 10.1016/0147-0272(91)90012-y. [DOI] [PubMed] [Google Scholar]
  8. Jeremic B., Shibamoto Y., Acimovic L., Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol. 1996 Apr;14(4):1065–1070. doi: 10.1200/JCO.1996.14.4.1065. [DOI] [PubMed] [Google Scholar]
  9. Kawato Y., Aonuma M., Hirota Y., Kuga H., Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991 Aug 15;51(16):4187–4191. [PubMed] [Google Scholar]
  10. Le Chevalier T., Arriagada R., Quoix E., Ruffie P., Martin M., Tarayre M., Lacombe-Terrier M. J., Douillard J. Y., Laplanche A. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst. 1991 Mar 20;83(6):417–423. doi: 10.1093/jnci/83.6.417. [DOI] [PubMed] [Google Scholar]
  11. Masuda N., Fukuoka M., Fujita A., Kurita Y., Tsuchiya S., Nagao K., Negoro S., Nishikawa H., Katakami N., Nakagawa K. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group. Br J Cancer. 1998 Jul;78(2):251–256. doi: 10.1038/bjc.1998.473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mattson K., Holsti L. R., Holsti P., Jakobsson M., Kajanti M., Liippo K., Mäntylä M., Niitamo-Korhonen S., Nikkanen V., Nordman E. Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol. 1988 Mar;24(3):477–482. doi: 10.1016/s0277-5379(98)90020-7. [DOI] [PubMed] [Google Scholar]
  13. Morton R. F., Jett J. R., McGinnis W. L., Earle J. D., Therneau T. M., Krook J. E., Elliott T. E., Mailliard J. A., Nelimark R. A., Maksymiuk A. W. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med. 1991 Nov 1;115(9):681–686. doi: 10.7326/0003-4819-115-9-681. [DOI] [PubMed] [Google Scholar]
  14. Mountain C. F. A new international staging system for lung cancer. Chest. 1986 Apr;89(4 Suppl):225S–233S. doi: 10.1378/chest.89.4_supplement.225s. [DOI] [PubMed] [Google Scholar]
  15. Negoro S., Fukuoka M., Masuda N., Takada M., Kusunoki Y., Matsui K., Takifuji N., Kudoh S., Niitani H., Taguchi T. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst. 1991 Aug 21;83(16):1164–1168. doi: 10.1093/jnci/83.16.1164. [DOI] [PubMed] [Google Scholar]
  16. Oken M. M., Creech R. H., Tormey D. C., Horton J., Davis T. E., McFadden E. T., Carbone P. P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649–655. [PubMed] [Google Scholar]
  17. Perez C. A., Stanley K., Grundy G., Hanson W., Rubin P., Kramer S., Brady L. W., Marks J. E., Perez-Tamayo R., Brown G. S. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung: report by the Radiation Therapy Oncology Group. Cancer. 1982 Sep 15;50(6):1091–1099. doi: 10.1002/1097-0142(19820915)50:6<1091::aid-cncr2820500612>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  18. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Petrovich Z., Stanley K., Cox J. D., Paig C. Radiotherapy in the management of locally advanced lung cancer of all cell types: final report of randomized trial. Cancer. 1981 Sep 15;48(6):1335–1340. doi: 10.1002/1097-0142(19810915)48:6<1335::aid-cncr2820480614>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  20. Roswit B., Patno M. E., Rapp R., Veinbergs A., Feder B., Stuhlbarg J., Reid C. B. The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo. Radiology. 1968 Apr;90(4):688–697. doi: 10.1148/90.4.688. [DOI] [PubMed] [Google Scholar]
  21. Sause W. T., Scott C., Taylor S., Byhardt R. W., Banker F. L., Thomson J. W., Jones T. K., Cooper J. S., Lindberg R. D. Phase II trial of combination chemotherapy and irradiation in non-small-cell lung cancer, Radiation Therapy Oncology Group 88-04. Am J Clin Oncol. 1992 Apr;15(2):163–167. doi: 10.1097/00000421-199204000-00014. [DOI] [PubMed] [Google Scholar]
  22. Sause W. T., Scott C., Taylor S., Johnson D., Livingston R., Komaki R., Emami B., Curran W. J., Byhardt R. W., Turrisi A. T. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995 Feb 1;87(3):198–205. doi: 10.1093/jnci/87.3.198. [DOI] [PubMed] [Google Scholar]
  23. Schaake-Koning C., van den Bogaert W., Dalesio O., Festen J., Hoogenhout J., van Houtte P., Kirkpatrick A., Koolen M., Maat B., Nijs A. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992 Feb 20;326(8):524–530. doi: 10.1056/NEJM199202203260805. [DOI] [PubMed] [Google Scholar]
  24. Tamura K., Takada M., Kawase I., Tada T., Kudoh S., Okishio K., Fukuoka M., Yamaoka N., Fujiwara Y., Yamakido M. Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts. Jpn J Cancer Res. 1997 Feb;88(2):218–223. doi: 10.1111/j.1349-7006.1997.tb00369.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Trovò M. G., Minatel E., Veronesi A., Roncadin M., De Paoli A., Franchin G., Magri D. M., Tirelli U., Carbone A., Grigoletto E. Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma. A randomized study. Cancer. 1990 Feb 1;65(3):400–404. doi: 10.1002/1097-0142(19900201)65:3<400::aid-cncr2820650304>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  26. Trovó M. G., Minatel E., Franchin G., Boccieri M. G., Nascimben O., Bolzicco G., Pizzi G., Torretta A., Veronesi A., Gobitti C. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1992;24(1):11–15. doi: 10.1016/0360-3016(92)91014-e. [DOI] [PubMed] [Google Scholar]
  27. Wingo P. A., Tong T., Bolden S. Cancer statistics, 1995. CA Cancer J Clin. 1995 Jan-Feb;45(1):8–30. doi: 10.3322/canjclin.45.1.8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES